|Videos|October 26, 2022
Key Trial Data in Urothelial Carcinoma Treatment from ESMO 2022
Srikala Sridhar, MD, MSc, FRCPC, and Jeanny B. Aragon-Ching, MD, FACP, wrap up their review of updates in urothelial carcinoma by highlighting exciting data presented at ESMO 2022.
Advertisement
Episodes in this series
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved pembrolizumab plus enfortumab vedotin in MIBC.
Advertisement
Advertisement
Trending on OncLive
1
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
2
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
3
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
4
Imaging Cadence, Radiation Timing, and Osimertinib Dosing Frame CNS Management Decisions in EGFR-Mutated NSCLC
5